Max Healthcare Institute Limited (543220) Earnings Call Transcript & Summary

November 3, 2026

BSE Limited IN Health Care Health Care Providers and Services earnings 49 min

Earnings Call Speaker Segments

Operator

operator
#1

Good day, everyone, and welcome to the Max Healthcare Institute Limited Earnings Conference Call. Kindly be aware that this conference is being recorded. At this point, I turn the conference over to Mr. Suraj of CDR India. Thank you, and the floor is yours, Suraj.

Suraj Digawalekar

unknown
#2

Thank you, Roya. Good afternoon, everyone, and thanks for being with us on Max Healthcare's Q2 and H1 FY '27 Earnings Conference Call. Joining us are Mr. Abhay Soi, Chairman and Managing Director; Mr. Yogesh Sareen, Group Director and Chief Financial Officer; and Mr. Keshav Gupta, Group Director, Growth, M&A and Business Planning. We'll start with opening remarks from the management, and after that we'll open the forum for an interactive Q&A session. Before we begin, I'd like to note that certain statements in today's call may be forward-looking in nature, and a disclaimer to that effect was included in the earnings presentation shared with you earlier. I'd now like to invite Abhay to give his opening remarks. Thank you, and over to you, Abhay.

Abhay Soi

executive
#3

Good morning, everyone, and thank you for being with us today for Max Healthcare's earnings call covering the second quarter and first half of FY '27. During the second quarter we built on our momentum, with revenue up 20%, operating EBITDA up 18% and PAT up 10%. Across the hospital network, demand for quality healthcare continues to be strong, and occupancy stayed steady at 77% even though operational bed capacity rose 14% year on year. At all 3 brownfield expansions — Max Nanavati in Mumbai, Max Mohali and Max Smart at Saket, Delhi — occupancy and revenue have ramped up nicely and are in line with what we expected. At Max Smart, the 260 newly commissioned beds reached EBITDA breakeven within 3 months of operations being Q2, and they are now seeing high occupancy levels. That said, the early ramp-up of these beds did weigh on EBITDA at the Saket Complex in Q2. Leaving out the Saket complex, revenue rose 20% and EBITDA rose 25%. We expect to commission the remaining 140 beds after Diwali-Puja. These fast ramp-ups have encouraged us, and we keep looking for ways to add capacity at our existing hospitals. On that front, the Board has approved an investment of INR 415 crores to add 209 brownfield beds at Max Noida, Max Vishali and BLK Max, plus an MLCP multi-level car park tower at BLK at a cost of roughly INR 85 crores.

Abhay Soi

executive
#4

That falls under the INR 415 crores. The bulk of this capacity should come online within 18 to 24 months. In the quarter, we added 202 brownfield beds to operational capacity, primarily at Max Smart, Max Lucknow, Max Noida and Max Dwarka. We have also begun services at the new oncology block at Max Dwarka, which will allow us to add roughly 20 beds to that hospital in Q3 FY '27. After the rights issue by Kalinga Hospital Limited, our shareholding rose to 66%. A fresh leadership team is now in charge at Max Bhubaneswar, and clinical teams have been brought in across gastroenterology, GI surgery, neurosurgery and orthopedics. That hospital posted revenue of INR 38 crores and EBITDA of INR 4 crores for the quarter. Renovation of the facility has started, and the first portion will begin rolling out near the end of the year. Turning now to the Q2 performance highlights. Network average occupancy came in at 77%, comparable to last year even with a 14% rise in operational bed capacity. Occupied bed days rose 13% year-on-year and 7% quarter-on-quarter. Average revenue per patient for the quarter was INR 2.31 lakhs, up 8% year-on-year.

Abhay Soi

executive
#5

Part of this growth came from institutional bed share falling to 29% from 34% last year. Network gross revenue was INR 3,219 crores, versus INR 2,692 crores in Q2 last year and INR 2,982 crores in the prior quarter. That works out to a 20% year-on-year rise and 8% quarter-on-quarter. Because we discontinued select high-value chemotherapy drugs for institutional patients following CGHS rate revisions last year, oncology's share of inpatient revenues fell to 21% from 26% in Q2 FY '26. Leaving oncology aside, gross revenue rose 25% and ARPP rose 11% year-on-year. International patient revenue came to INR 307 crores, a significant 33% year-on-year increase, and it now makes up 10% of healthcare revenue from hospitals. Digital revenue — from online marketing activities, web-based appointments and digital lead management — was INR 1,099 crores, roughly 34% of overall revenue. Website traffic surpassed 1.14 crore sessions in the quarter, up 44% year-on-year. Operating EBITDA for the quarter was INR 820 crores, against INR 694 crores in Q2 FY '26 and INR 704 crores in the previous quarter, reflecting 18% year-on-year growth and a significant 16% quarter-on-quarter increase, while EBITDA per bed rose 4% year-on-year to INR 77 lakhs per annum.

Abhay Soi

executive
#6

Our operating EBITDA margin came in at 26.8%, which is comparable to Q2 FY '26 even though operational bed capacity rose by 14%, and that reflects roughly 200 basis points of improvement versus the trailing quarter. Profit after tax for the network reached INR 448 crores, compared with INR 406 crores in Q2 last year, after normalizing for a onetime tax gain of INR 149 crores and INR 357 crores in the prior quarter, which works out to 10% growth year-on-year and 26% quarter-on-quarter. Free cash flow generated by the network during the quarter was INR 500 crores, and out of that, INR 292 crores went into ongoing capacity expansion in projects while INR 195 crores was disbursed toward dividend. Net debt for the network was INR 2,369 crores, versus INR 2,384 crores as of the end of June 2026, and the net debt-to-EBITDA ratio stayed below 1. As part of our ongoing efforts to support local communities, we gave free treatment to more than 57,000 patients from economically weaker sections of society, valued at INR 90 crores at hospital tariff, which reflects 47% growth year-on-year. Revenue and profitability both continued to grow steadily across our two strategic business units. MAX@Home posted revenue of INR 86 crores, a robust 37% increase year-on-year. It provides 16 specialized service lines spanning 15 cities, with over 56% repeat transactions.

Abhay Soi

executive
#7

Max Lab posted INR 66 crores in revenue, which works out to 24% growth year on year. The company delivers services across more than 60 cities and treated over 7 lakh patients in the quarter. Let me now turn to where things stand on the expansion projects that will come on stream in the coming years. The remaining 205 beds at Max Nanavati and Max Smart, Saket, Delhi, are set to open after Diwali-Puja. At Max Lucknow, 100 beds within the existing 460-bed facility will be commissioned across the next 2 quarters. At Max Noida, 85 beds should be commissioned by December 2027. For the 500 beds at Sector 56 Gurgaon, we anticipate beginning phase commissioning of that facility by the close of this financial year. On the 250 beds at Bhubaneswar, renovation of the existing facility is in progress, and we expect phase completion within the next 12 to 15 months, with the first portion of the renovation handed over by the end of this current calendar year. For the 100 beds at Max Nagpur, project work remains on track, and commissioning is expected by December 2027. The 400 beds at Zirakpur, Mohali are on schedule, and we expect to commission them by December 2027. The 200 beds at Pitampura are on track, with commissioning expected in FY 2029.

Abhay Soi

executive
#8

At Patparganj, with 400 beds, we anticipate commissioning by the close of FY 2029. For the 260 beds at Max Dwarka — we're building a new tower there, a brownfield project, which represents the next phase since Dwarka Hospital is operating at full capacity — commissioning should happen by FY '30. At Max Nanavati, 270 additional beds under the Phase 2 project: work has begun, and we'll be commissioning by FY '30. For the 450 beds in Pune, the IOD has been received. That project is expected to be commissioned by FY '30. At Max Vishali, 200 beds — a new tower is being built there, brownfield. Construction is underway, and we expect commissioning, again, by FY 2030. For 400 beds at Shaheed Path in Lucknow Phase 1, we are awaiting formal environmental clearance as well as building plans before starting construction activity at the site. Commissioning is expected in Phase 1 by FY '30. And lastly, turning to an overview of the company's performance for the first half of financial year 2027. Total bed capacity came in at roughly 6,200, up 20% year-on-year. Network gross revenue was INR 6,200 crores, a rise of 18% year-on-year. Operating EBITDA reached INR 1,524 crores, posting growth of 17% year-on-year, and operating EBITDA per bed increased 4% year-on-year to INR 74 lakhs.

Abhay Soi

executive
#9

Our operating EBITDA margin came in at 25.9%, which is comparable to H1 FY '26. That held up even though total bed capacity grew 20% year-on-year. On profit after tax, the network posted INR 805 crores versus INR 750 crores a year earlier, after normalizing for a onetime tax gain of INR 149 crores, which works out to 7% growth year-on-year. During the first half, operations generated INR 897 crores in free cash flow. Once interest, tax, working capital changes and routine CapEx were accounted for, INR 629 crores went toward ongoing expansion projects and facility upgrades at new units. A further INR 386 crores was spent on the acquisitions of Kalinga Hospital Limited, Bhubaneswar, and Yerawada Properties Private Limited, Pune, while INR 195 crores was distributed as dividend. With that, we'll now open the floor for any questions you may have.

Operator

operator
#10

<<operator_script>> Our first question comes from Tausif at BNP Paribas.

Tausif Shaikh

analyst
#11

I’ll start with my first question, which has to do with the hospital disempanelment noted in the footnote. Could you share how many hospitals have been disempaneled, and which hospitals those are? Also, do you intend to raise that number further? And what’s the reasoning behind this?

Yogesh Sareen

executive
#12

In May, we disempanelled BLK, and after that CGHS, and then we went ahead with the railways and so on, since those parties weren't settling their dues with us, and ECHS at Shalimar Bagh as well. Those are the accounts we removed from the panel. However, given the pressure we're feeling in the CPI business, the decision will ultimately have to be taken at the level of each hospital, correct?

Abhay Soi

executive
#13

I mean, that's a typical path — with the more mature or older hospitals, you observe them disempanelling and refining the payer mix, whereas with the newer hospitals, you empanel them and bring on more institutional business.

Tausif Shaikh

analyst
#14

Sir, I just want to get a clearer picture here — were any hospitals making these choices on their own, voluntarily, overnight? And would you be looking to bring the upcoming Gurugram hospitals into the CGHS and ECHS panels?

Abhay Soi

executive
#15

Yes, we will pursue the new hospital. And as I mentioned, with regard to the older hospitals, you panel them. For instance, most of the hospitals that go the brownfield route do almost no institutional business. And once that new brownfield capacity is in place, you begin empaneling and you begin doing institutional business as well.

Tausif Shaikh

analyst
#16

That's useful. My next question concerns the rate at which doctors are leaving and how the Gurugram market is behaving. A competitor of yours recently brought a new hospital into service, yet we haven't observed any significant departure of top doctors from the market. I just wanted to hear your thinking. Have you begun conversations with physicians, and what makes you confident that, once we commercialize Gurugram, we'll be able to bring good clinicians on board very quickly?

Abhay Soi

executive
#17

I mean, clinician attrition runs at roughly 1% per year, and it might tick up slightly or it might not. But bear in mind, it's not like a huge number of hospitals are opening up. There are already plenty of hospitals out there. We have plenty of hospitals. Anyone serving as head of admin at a hospital wants to run a hospital within 4 to 5 years. If you're a senior consultant, you're looking to lead a program in a few years, and so on. So career progression has to be offered as well. The reality is that if you don't grow and you don't build additional hospitals, your next line will leave and join the competition. I think the fact that we're building our own hospital in Gurugram and expanding in other locations across Delhi NCR lets us retain people and offer opportunities to the second line as well, right? I mean, keep in mind, we have 14 facilities in Delhi NCR, and more than 4,000 clinicians work for us full-time here.

Tausif Shaikh

analyst
#18

If I could just ask one final question. Regarding the recent government-imposed trade margin cap on non-scheduled drugs, what impact might that have on sales and EBITDA? Even a rough figure would be useful.

Abhay Soi

executive
#19

We haven’t fully figured that out yet.

Operator

operator
#20

We’ll take our next question from Neha Manpuria at Bank of America.

Neha Manpuria

analyst
#21

Abhay, you said the Smart commissioning affected the Saket complex somewhat. From what you understand, how long would Saket need to get back to normal? And since we have a fair amount of brownfield capacity coming up, do you think similar kinds of disruption could show up at our other facilities that we ought to plan for?

Abhay Soi

executive
#22

No. Look, my consistent guidance has been that a brownfield differs from a greenfield — with a greenfield, reaching breakeven can take anywhere from 6 months to 1 year. For greenfield, our typical guidance is 1 year. A brownfield reaches breakeven inside the first quarter itself. And that's the guidance I've consistently given, right? Whenever you add expanded capacity in any location, you'll carry a preoperative expense, because the first thing is that you hire employees. You might not be bringing on senior management, or maybe not very senior consultants or clinicians, but everyone else does get hired. So prior to commissioning, you're bearing a cost. Then once commissioning happens, occupancy first ramps up, followed by the quality of revenue, and after that EBITDA ramps up. Within the first quarter, you break even in the brownfield. And as we've observed, Mohali opened first. We broke even in the first quarter there, and then it ramped up. Nanavati Max in Mumbai was similar in that sort of way. And at Saket you're witnessing the same pattern. So the last quarter was really its first quarter — a full quarter of operations. And even though it ramped up beautifully by the end of that quarter, I mean, there was an EBITDA drag in that complex, and because of that.

Abhay Soi

executive
#23

It's really just a one-quarter effect from that thing you've got in a brownfield. Even so, there is a drag. So what was — now what's the size of that drag, given that overall you have EBITDA growth of about 20%? But if I take out that complex, it's 25%. Yet by next quarter, things get back to normalcy, correct? Because whatever drag has to occur, the heaviest burden you carry is preoperative and then — right away once operations begin.

Neha Manpuria

analyst
#24

Right, got it. So what you're saying is that since we're still in ramp-up mode, that pulled profitability down.

Abhay Soi

executive
#25

Yeah, absolutely — absolutely. So here's how it works: picture us opening 250 beds, right? During month one, you'll fill 50 beds; in month two, you'll fill another, say, 100 or 150 beds; and come month three, or the close of month three, or month four, all 250 beds are already occupied. That's precisely why we're doing Diwali-Puja and launching an extra 150 beds at that site, correct? Yet every one of those 150 beds then begins contributing to the bottom line, more and more and more. Your EBITDA trajectory kind of overtakes your revenue trajectory — and even all the operating leverage you get.

Neha Manpuria

analyst
#26

Right. So on your point about the EBITDA margin ramping up, say, in the second or third quarter after commissioning — we should probably see this drag normalize by March. Is that a fair way to understand it, based on...

Abhay Soi

executive
#27

For the most part, that's already normalized. But yes, you will see — I mean, as I said, look, you get a drag when occupancy sits at 50 beds out of 400, right? Your drag — once occupancy is 250 beds or more out of the 400 you've added, then the drag is that much smaller. I mean, you're already reaching very high numbers. What you're seeing covers the whole quarter.

Neha Manpuria

analyst
#28

Got it. All right, that’s…

Abhay Soi

executive
#29

I mean, the growth is like a hockey stick. You see — picture a hockey stick.

Neha Manpuria

analyst
#30

Alright, my second question is just about Mumbai — if I look at the bed additions you report by state in Maharashtra, is it reasonable to assume that for Phase 2, the block that has to be demolished has already been demolished? And that's the reason the ramp-up we're expecting at Nanavati isn't showing up in Maharashtra's operational beds?

Abhay Soi

executive
#31

Exactly. So those beds have been discontinued, and the remaining 40 or 50 beds that need to begin at Nanavati will begin at the end of the Puja. Please keep in mind that the quality of the beds that have been brought down is basically economy class. So they weren't — the quality of those beds isn't very significant.

Neha Manpuria

analyst
#32

All right, and that brings me to my final question...

Abhay Soi

executive
#33

So the drag is basically the same. But yeah, Mumbai — what I mean is, Mumbai has already gotten past that stage where revenue ramps up and EBITDA ramps up.

Neha Manpuria

analyst
#34

Alright, for my final question — I realize you mentioned that the oncology margin cap is still under review. Still, at a high level, there has been quite a lot of chatter regarding drug devices, consumables, and similar items, plus the margins hospitals earn. If you could share any thoughts on what you believe is being misconstrued, or how you would likely lay out your stance on this matter, that would be extremely useful.

Abhay Soi

executive
#35

I believe the sector's stance has now been placed before the court. The matter is sub judice. And I think it's fairly evident where the hospital providers stand, and the government's position is equally clear. So rather than relying on what you hear in the media and so on and so forth, I would encourage everyone to actually look at what the government's pleadings say and what the statements were, whether from the government or the hospital sector. I think the hospital sector largely maintains that overall profitability — the median net profit across the whole sector, if I look at last quarter's figures, comes to roughly 9%, if I'm not mistaken, in a capital-intensive sector. But historically, this has been an industry priced on products rather than one priced on services. So we may well need to recalibrate that going forward, depending on the pulls and pushes. But I think that's where things stand. But as I said, the matter is — I think many, many wise heads will be offering their views on it, and so be it.

Operator

operator
#36

Damayanti Kerai from HSBC has the next question.

Damayanti Kerai

analyst
#37

My question concerns what you said about the shift in payor mix. So, as you mentioned, you'll continue assessing the mix exposure to the CGHS channel, et cetera. And I believe during the quarter, you reported that revenue contribution from this channel came in at around 18.5%, which is 300 basis points lower than the prior year. So is this the revenue share level you plan to keep? Or will there be volatility depending on how you view the change in the fair mix part?

Abhay Soi

executive
#38

No — what we're doing is responding as new capacities become available. Those capacities are going to take on CGHS, institutional business, and so on. And once some of those capacities mature, they'll shift away from that business. Part of this revenue decline also comes from discontinuing high-value drugs as well as oncology — those, as you can see, are actually a result of CGHS, right? So that's another reason you're seeing that percentage reduction there.

Damayanti Kerai

analyst
#39

Sure. Earlier you said you'd clearly want to reduce exposure to the institutional channel. So do you have a number in mind for where you intend to go?

Abhay Soi

executive
#40

No, no — I really don’t believe anyone intends to cut back how much we serve the institutional channel. The ideal outcome for us, I mean, is that when we add capacity at a given location, we can then serve both types of business. But what occurs is that, automatically, in a place where capacity is under pressure, your lower ARPOB business — or rather the lower ARPP business — automatically begins to be distilled away. Still, the ideal scenario is if we’re able to keep adding capacity there. I mean, take an example of — I mean, I’ll give you a very specific instance of the hospital in Mumbai, where there was no institutional business. But since you carried out the capacity expansion at that site, you were able to add more capacity, and we were able to accommodate it. So we began — we empaneled that hospital. Whereas at another hospital in BLK, where capacity is under pressure, you’ve depaneled it. So that kind of thing will keep happening.

Damayanti Kerai

analyst
#41

On this empanelment and disempanelment question — is that going to be decided case by case again, correct? I'd just like to get a clearer picture: say CGHS has been disempaneled at BLK hospital. So going forward, if you wanted to reempanel, would that be a possibility? Or how does that work, then?

Abhay Soi

executive
#42

We haven't been taken off any panel. We've taken ourselves off. You're on a panel, right, and you decide not to be, or whatever, then you apply to them and you get yourself removed from it. And yes, I mean, if and when we expand that particular facility, we may, at that point, put ourselves back on. But let's say, with BLK, you're only adding about 85-odd beds. So you may not do that -- 64 beds, you may not do that. It's not a large capacity that you're sort of adding on.

Damayanti Kerai

analyst
#43

Got it. My second question concerns the regulatory headwinds we're seeing specifically for oncology drugs — I think both last year and in the recent development. So while the matter is before the court, what other segments do you think could really help offset the impact of these regulatory headwinds in oncology, and would you prefer some other sector over oncology as your key driver?

Abhay Soi

executive
#44

We don't — it's — we respond to how diseases weigh on the market, correct? And you've witnessed — it isn't that other diseases aren't expanding. Every one of them is up 25% year-on-year, right? So growth has been — in the end, you wind up with inventory sitting there. Even though revenue drops, it isn't as though occupied bed days fall to that same degree, right? I mean, so — I mean, I don't view that as — I don't view that as anything that's going to have an impact.

Damayanti Kerai

analyst
#45

All right, then. As for the leading 4 or 5 segments, we typically refer to them as Congo. That share, therefore, ought to keep growing, with other areas offsetting a portion of it.

Abhay Soi

executive
#46

No, no, you have to look at this with some perspective. There are inventories involved. There are different specialties and patients. When someone shows up at the ER or arrives for elective surgery, we don't ask them, are you an oncology patient? Okay, are you a cardiac patient, so cardiac patient, please wait, and the oncology patient, please, you get some kind of accelerated admission path or whatever. It doesn't work that way, right? At that moment, whichever bed happens to be free. Now, if a particular — we have not seen a reduction in occupied bed days for any particular specialty.

Operator

operator
#47

Our next question comes from Karan Vora at Goldman Sachs.

Karan Vora

analyst
#48

Let me start with the Gurgaon greenfield, which should be up and running by year-end. I just want to get a sense of how many — in Phase 1, are we expecting all 500 beds, or will it be split? And what kind of EBITDA impact might come from that? Any breakeven timelines, et cetera, that you'd like to highlight?

Abhay Soi

executive
#49

Right. So usually we begin with 150 to 200 beds, all right, then ramp up, reach breakeven, and after that we attempt to open additional beds, correct? And in Dwarka you've witnessed a similar kind of pattern too. Opening all 500 beds makes no sense when you lack day one occupancy. You can't fill 500 beds on day one; that's not how it works. A ramp-up period still exists. When we opened 300 beds at Dwarka, we posted an EBITDA loss of INR 30 crores. You can work it out — I don't know, if I had to draw a line in the sand, INR 40 crores to INR 50 crores. That number is still being worked on, but it shouldn't exceed that.

Karan Vora

analyst
#50

Understood. On the second question, which concerns CGHS: you said we've successfully executed this approach of admitting CGHS patients into new beds. So I just want to understand, in those cases, how do you make sure the hospital's premium perception isn't harmed when a large number of CGHS patients come through? Or even in hospitals where occupancy is north of 75%, 80%, how do you ensure — since that means the hospitals are entirely full, correct? — how do you ensure that service levels and patient perception aren't affected by occupancy that high?

Abhay Soi

executive
#51

I'm not sure I follow. I mean, when you open a new hospital — I mean, if I had occupancy of 500 beds, I'd probably open the 500 beds. When you open a new hospital, you don't have occupancy of 500 beds, right? So I mean, first and foremost, what you do is you take business, lower ARPOB business, lower clinical mix, lower this thing, whatever else it is. The perception doesn't get affected by institutional business or whatever else it is. I think 40% of our business is up country.

Yogesh Sareen

executive
#52

Karan: So we don't specifically aim to create a different perception for each patient pool. The system doesn't favor any particular sponsor's patients. What occurs is that when a hospital reaches capacity owing to the economic benefit, we essentially deempanel that full hospital as a later stage. But the hospital performs normally.

Abhay Soi

executive
#53

They begin distilling automatically.

Karan Vora

analyst
#54

Understood. One more quick question. When we disempanel, the empanelment itself also covers a set period, correct? Perhaps empanelment for 1 year or 2 years. So after we empanel with a given hospital under that CGHS scheme, what is the shortest period during which we are required to stay with it?

Abhay Soi

executive
#55

No, no — it's a 6-month thing. You've got an evergreening process running on a 6-month cycle. You sign an agreement, and every 6 months you keep evergreening it.

Yogesh Sareen

executive
#56

And there's a 1-month notice period, correct? So with a panel, notice can be given by either side.

Operator

operator
#57

Our following question comes from Rahul Jeewani at IIFL Securities.

Rahul Jeewani

analyst
#58

Regarding the 2 greenfields — Sector 56 Gurgaon and Zirakpur, Mohali. On 56 Gurgaon, you mentioned an EBITDA loss of roughly INR 40 crores to INR 50 crores. So, is that loss going to be limited to just the first few quarters, or do you expect that drag to persist through the entire year of FY '28? And in a similar vein, could you also speak to what sort of EBITDA drag we ought to factor in from Mohali in FY '29?

Abhay Soi

executive
#59

Usually, our practice — what I mean is, we generally target a breakeven of 1 year. In Dwarka, we reached breakeven within 6 months. So I suppose the answer will land somewhere around there. In Delhi, at Dwarka, we had 300 beds. As I mentioned, it carried an EBITDA loss of INR 30 crores, INR 35 crores. That figure represents the cumulative peak EBITDA loss.

Rahul Jeewani

analyst
#60

Alright, thanks Abhay. And should Zirakpur and Mohali see a comparable loss in FY '29 as well? Or do you think that figure might come in a bit lower?

Abhay Soi

executive
#61

Lower, lower, significantly lower. INR 30 crores. We'll figure out the figures and provide a more exact number, but approximately that. You see, we come to know—we have a clearer picture once we begin onboarding teams, correct? Once you start bringing clinician teams on board, et cetera, that is when you understand what the trough is, what the pre-operating expenses are, and what your day 1 expenditure will be.

Rahul Jeewani

analyst
#62

Yeah, yeah, yeah. And regarding, say, the effect of the...

Abhay Soi

executive
#63

If we're launching something in December of next year — 12 months out — we haven't begun bringing the teams on board, correct? So I don't have any idea what that team will cost. So I'm not trying to dodge the question, but honestly, I don't have a — at this point I can only give you a line-in-the-sand answer.

Rahul Jeewani

analyst
#64

Yeah, yeah, yeah. Now, regarding your second question, it concerns the effect of discontinuing the chemotherapy drugs. That effect began in the third quarter of last year. So as that effect laps itself in the third quarter of this year, would you expect the top line growth we delivered—roughly 20%—to speed up further as we move into the third quarter and the fourth quarter?

Abhay Soi

executive
#65

That occurred in — yes, that ought to be true, since you're still working from a lower base.

Rahul Jeewani

analyst
#66

And wouldn't that also be helped by the fact that some of these incremental brownfield and greenfield expansions would be coming online and contributing as well?

Abhay Soi

executive
#67

That’s correct.

Operator

operator
#68

Our next question comes from Dhara Ganatra of UTI PF.

Analyst

analyst
#69

My question mostly concerns the trade margin cap that's come out. So what I'd like to understand is the kind of share of pharmacy revenues and EBITDA — pharmacy's share in both revenue and EBITDA? And within that, how much would be medical oncology?

Abhay Soi

executive
#70

Sorry, could you say that again, please?

Analyst

analyst
#71

How much of your revenue and EBITDA comes from pharmacy? And within that, could you also point out what portion is medical oncology? So leaving out surgeries and looking only at oncology, what would the pharmacy share be?

Yogesh Sareen

executive
#72

So actually, chemo makes up roughly 30% of total oncology revenue, correct? And inside that, as you probably know, you've got a blend of some ORG products plus monopoly products, and those aren't touched by this price cap and so on, right? So for that portion, we really have to — once we receive the revised MRPs, the new ones, we'll be in a position to see what the impact looks like and so forth. But that's essentially the situation. So in short, 30% is chemotherapy. And within it, part is ORGs and monopolies, and another part is generic drugs. The monopoly and ORG pieces won't feel any effect from this one, right?

Abhay Soi

executive
#73

Regarding CGHS and the rest, the impact has already occurred — that was last year.

Yogesh Sareen

executive
#74

CGHS is already factored in at this point.

Abhay Soi

executive
#75

When it comes to how CGHS affects oncology — that's what I mean...

Yogesh Sareen

executive
#76

Right. That’s already factored in at this point.

Analyst

analyst
#77

Right, so what kind of impact have you all assessed internally as management? Is there anything you'd like to put out there as an estimate?

Abhay Soi

executive
#78

No, we haven't. We're still figuring that out. As I mentioned, we haven't — the only piece we do know is that the CGHS impact won't be present, since that effect already occurred last year.

Operator

operator
#79

Bino Pathiparampil from Elara Capital has the next question.

Bino Pathiparampil

analyst
#80

Just to follow up on that earlier question, what would you say pharmacy contributes to total revenue — all pharmacy combined, not only oncology?

Abhay Soi

executive
#81

I didn't provide a figure for you.

Bino Pathiparampil

analyst
#82

All right, but broadly speaking, might that figure land at 15%, 25%, or 35%?

Abhay Soi

executive
#83

It's about bundled services. Take, for example, a chemo treatment — but then the mixing charges and so on come bundled with it. So figuring out which piece is which is a bit tough, because with packages you have to split things apart. How do you go about working that out?

Bino Pathiparampil

analyst
#84

Got it. And how much of overall revenue would come from package services versus the pay-as-you-go type of offering?

Yogesh Sareen

executive
#85

It really depends on which side you mean — whether that's self-pay or a particular insurer. But the range would fall somewhere from 20% to 30%.

Abhay Soi

executive
#86

CGHS won’t — this is off the…

Yogesh Sareen

executive
#87

Since CGHS likewise includes a certain package.

Bino Pathiparampil

analyst
#88

Apologies — when you say 20% to 30%, does that refer to packed services?

Yogesh Sareen

executive
#89

It really depends on the specific customer.

Bino Pathiparampil

analyst
#90

All right, so on the other 70%, you'd be in a position to provide a contribution of revenue — correct, the pharmacy's contribution to revenue, right?

Abhay Soi

executive
#91

We can’t give you that breakdown. We understand the total pharmacy figure, but we’re not in a position to say what the balance is, what the pharmacy is, et cetera. That isn’t how we tend to look at the numbers.

Bino Pathiparampil

analyst
#92

All right, though what we're after is more of a ballpark figure for that 70% area where we…

Abhay Soi

executive
#93

You'd need to separate out the services, and that can't be done. I mean, the total net profit, you know.

Operator

operator
#94

Our next question comes from Sidharth Negandhi at CWC.

Sidharth Negandhi

analyst
#95

You said ex-oncology revenue growth is 25%. Could you help me understand what that would translate to in terms of EBITDA growth as well? And second, earlier in the call you alluded to not really having a particular set patient mix, but there's also been a decrease in cardiology salience, which means cardiology would have grown more slowly than overall revenue, while we don't see any slowdown in cardio growth in the allied space in pharma. Is there anything that might be happening there because of increasing competitive intensity? Or what's your read on why cardiology growth is slower? Yes, those are the 2 questions.

Abhay Soi

executive
#96

Cardiology tends to follow a seasonal pattern. There's a winter season, when cardiology cases come in at a higher incidence, and that's also the period when orthopedic cases occur less often. So when you look at it, are you focused on quarter-on-quarter or year-on-year?

Sidharth Negandhi

analyst
#97

Year-on-year.

Yogesh Sareen

executive
#98

No, I'm not certain I follow your question. I believe you're referring to oncology — yes, I think oncology is affected because of the chemotherapy drugs being discontinued, correct? So because of that, we've stated that if we exclude oncology, then revenue growth is clearly higher, since last year you had those chemotherapic drugs and this year you don't. And that's why you see that oncology's share is also lower as a percentage of total revenue, right?

Sidharth Negandhi

analyst
#99

Right. So, sir, what I was hoping to get a handle on is this: revenues excluding oncology are up 25%. Can you also help us see what that has meant for EBITDA growth? Is EBITDA growth likewise considerably higher owing to that same oncology effect? That's the first question. On cardiology, just to be clear, my comparison was year-on-year rather than quarter-on-quarter, and that's where the question came from.

Abhay Soi

executive
#100

Wouldn't EBITDA growth come in higher, right? So basically, even with that revenue leaving the books, your EBITDA margin ends up matching last year's.

Yogesh Sareen

executive
#101

No, we can't assign a value that isn't present in the P&L. We can't simply claim that this would have been the figure. So we don't want to engage in that type of number exercise, correct? So clearly, the decline in chemotherapy drugs affects the margin, correct? We mentioned previously that the total effect of this comes to approximately INR 100 crores annually, right, from chemotherapy drugs being discontinued. Still, we achieved a net gain of INR 200 crores on the CGHS price. That's the figure we provided before.

Abhay Soi

executive
#102

So you can’t have one without the other. What I mean is, if we look at it net-net, there was a gain from the CGHS price revision. One piece of that was oncology, where we had a loss. Right? But cardiology also went up by what? What’s the growth in cardiology?

Yogesh Sareen

executive
#103

18% growth.

Abhay Soi

executive
#104

Cardiology also grew 18% for us. So I was just getting to the question that came before.

Operator

operator
#105

Prashant Kshirsagar from Unived Corporate Research has the next question.

Prashant Kshirsagar

analyst
#106

I have a question about Noida Super Specialty Hospital. Could you provide the occupancy figures for Q1 and Q2, if possible?

Abhay Soi

executive
#107

Regarding Noida?

Prashant Kshirsagar

analyst
#108

Yes.

Abhay Soi

executive
#109

We won’t provide exact occupancy figures for individual hospitals.

Prashant Kshirsagar

analyst
#110

Alright. And then, on the 85 beds that are going to come online through the brownfield expansion in Noida — would that be on top of the 504 beds you currently have? Or is it going to be 377 beds plus?

Yogesh Sareen

executive
#111

That's part of the 500-bed complex — activated beds at 378, 380 beds — and you'll be adding 85 beds to that activated bed capacity.

Abhay Soi

executive
#112

At some point, when you go the brownfield route, there's an answer to be found, since your capacity utilization is elevated. If that weren't the case, you wouldn't be putting in 85.

Prashant Kshirsagar

analyst
#113

Right, so it’ll mainly be in the direction of that 700-bed hospital, which is going to be…

Abhay Soi

executive
#114

No, no—that's on top of it. That is extra.

Keshav Gupta

executive
#115

Sorry — to make sure it's clear, the whole site covers 18 acres. The existing building holds 500 beds — 504, 505 beds — and 80 of those are active. Another 85 beds will be brought online within that same complex. The remaining 11 acres sit unused, and there we're able to add 700 beds. That's a distinct phase, as noted in our earlier communications.

Prashant Kshirsagar

analyst
#116

All right, that's fine. Then my next question concerns Greater Noida. During the earlier presentations, you mentioned a land parcel sized for 400 beds. So does an existing hospital already operate in Greater Noida on your side, or is there none?

Abhay Soi

executive
#117

No, we don’t.

Yogesh Sareen

executive
#118

All we have in that location is a single parcel of land.

Prashant Kshirsagar

analyst
#119

Right, so all you’ve got there is a piece of land. Okay. That answers what I was asking.

Operator

operator
#120

The following question comes from Divya at Ajcon Global Services.

Analyst

analyst
#121

A lot of my remaining questions have already been covered. So I’ll limit myself to one on Max Lab and MAX@Home. This quarter we saw solid year-on-year growth of roughly 24% and 37%, respectively. Their contribution to the overall business, though, is still fairly small. So going forward, what are the main growth drivers for these 2 businesses? And over the next 3 to 5 years, do you expect them to become meaningful contributors to the group’s overall growth and profitability?

Abhay Soi

executive
#122

I believe the main things propelling this business remain exactly what they were previously. There's a genuine need out there, and both our patients and our brand are part of the answer. We also observed the same degree of robust expansion in earlier years. It typically comes in at plus/minus 4 or 5 percentage points, yet on a CAGR basis it has exceeded 20% to 25% across many years. It has been expanding nicely, in other words. It pleases us that this segment's share of total revenue holds steady, provided our remaining businesses maintain their own growth pace. As you know, those other businesses have likewise been expanding roughly 25% to 26% over the last 5 years. That's really the sole explanation, much like the international business, why it stays a smaller percentage — or, as a share of revenue, it stays flat, even though on a stand-alone basis it keeps growing. And naturally, we expect this to matter meaningfully in the years ahead. If we didn't, we wouldn't be running these businesses. We're not the kind of company that operates something merely because it's a short-term cash cow.

Abhay Soi

executive
#123

We view them as the vehicles of tomorrow, and we keep putting money into these businesses. It is already fairly profitable.

Operator

operator
#124

We’ll have time for one final question. That last question comes from Prince Goenka at Narnolia.

Prince Goenka

analyst
#125

Two questions from me. The first one concerns Bhubaneswar, where 80 beds are presently closed for renovation. What's the timeline for getting those beds operational? And over the next 2 to 3 years, what occupancy and EBITDA levels should we expect? The second question is about how employee and doctor-related costs are trending as a percentage of revenue. As newly added capacity matures, do we expect operating leverage to improve? Or will manpower costs keep pressuring margins?

Keshav Gupta

executive
#126

The initial stage, the renovation part, ought to take roughly 12 months. In the first phase, we should receive the OTs and beds in approximately 3 months' time. Over the following 2 to 3 years, we'll put up an additional tower with another 250 beds on that side. Regarding manpower, I didn't catch the question. Could you say it again? What did you ask about manpower operating leverage?

Prince Goenka

analyst
#127

As the recently added capacity matures, do you anticipate any operating leverage improving, or will manpower costs keep weighing on margins?

Keshav Gupta

executive
#128

With the new facilities that came online as brownfield capacity, you're clearly going to see operating leverage. That's the point we raised at the start of this conversation. Once that capacity fills up, operating leverage kicks in. The same thing will play out at Bhubaneswar too.

Prince Goenka

analyst
#129

Alright, one more thing I’d like to ask. For Q2, how much of that 20% revenue growth was driven by an increase in patient volumes, and how much came from better average bill realization per patient?

Keshav Gupta

executive
#130

As we noted before, the ARPPs and IP volume growth were disclosed in that section. Volume growth for patients came in at roughly 12%; volume growth was 12% to 13%.

Operator

operator
#131

Thanks a lot. We’ll treat that as the final question. At this point, I’d like to pass the conference to the management team for their closing remarks.

Abhay Soi

executive
#132

Much appreciated, all of you, for being with us on this call today. We value the time you've given us, and we're eager to connect with you again when we report next quarter. Thanks so much.

Operator

operator
#133

Thanks so much. That brings us to the end of today's call. Appreciate all of you being with us, ladies and gentlemen. You can go ahead and disconnect your lines now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Max Healthcare Institute Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Max Healthcare Institute Limited earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Max Healthcare Institute Limited or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.